Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.53
VNDA's Cash to Debt is ranked lower than
65% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. VNDA: 5.53 )
Ranked among companies with meaningful Cash to Debt only.
VNDA' s Cash to Debt Range Over the Past 10 Years
Min: 5.53  Med: 10000.00 Max: No Debt
Current: 5.53
Equity to Asset 0.60
VNDA's Equity to Asset is ranked lower than
62% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. VNDA: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
VNDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.18 Max: 0.94
Current: 0.6
0.01
0.94
Interest Coverage N/A
VNDA's Interest Coverage is ranked higher than
52% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VNDA: N/A )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: N/A
F-Score: 3
Z-Score: 1.20
M-Score: -3.66
WACC vs ROIC
14.90%
-945.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -35.00
VNDA's Operating margin (%) is ranked higher than
58% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. VNDA: -35.00 )
Ranked among companies with meaningful Operating margin (%) only.
VNDA' s Operating margin (%) Range Over the Past 10 Years
Min: -790.41  Med: -36.56 Max: 40
Current: -35
-790.41
40
Net-margin (%) -34.70
VNDA's Net-margin (%) is ranked higher than
58% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. VNDA: -34.70 )
Ranked among companies with meaningful Net-margin (%) only.
VNDA' s Net-margin (%) Range Over the Past 10 Years
Min: -788.46  Med: -36.27 Max: 40.25
Current: -34.7
-788.46
40.25
ROE (%) -29.82
VNDA's ROE (%) is ranked higher than
51% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. VNDA: -29.82 )
Ranked among companies with meaningful ROE (%) only.
VNDA' s ROE (%) Range Over the Past 10 Years
Min: -221.21  Med: -76.85 Max: 23.67
Current: -29.82
-221.21
23.67
ROA (%) -19.49
VNDA's ROA (%) is ranked higher than
57% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. VNDA: -19.49 )
Ranked among companies with meaningful ROA (%) only.
VNDA' s ROA (%) Range Over the Past 10 Years
Min: -176.39  Med: -19.06 Max: 12.81
Current: -19.49
-176.39
12.81
ROC (Joel Greenblatt) (%) -1057.64
VNDA's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. VNDA: -1057.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VNDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4993.01  Med: -1415.44 Max: 784.55
Current: -1057.64
-4993.01
784.55
Revenue Growth (3Y)(%) 30.90
VNDA's Revenue Growth (3Y)(%) is ranked higher than
83% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. VNDA: 30.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VNDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 90.4
Current: 30.9
0
90.4
EBITDA Growth (3Y)(%) -12.00
VNDA's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. VNDA: -12.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VNDA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.65 Max: -10.1
Current: -12
EPS Growth (3Y)(%) -1.20
VNDA's EPS Growth (3Y)(%) is ranked higher than
55% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. VNDA: -1.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VNDA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.85 Max: -1.2
Current: -1.2
» VNDA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

VNDA Guru Trades in Q2 2015

Steven Cohen 96,500 sh (New)
Jim Simons Sold Out
John Paulson 3,946,500 sh (-0.09%)
Paul Tudor Jones 21,194 sh (-15.22%)
» More
Q3 2015

VNDA Guru Trades in Q3 2015

Paul Tudor Jones 40,776 sh (+92.39%)
John Paulson 3,946,500 sh (unchged)
Steven Cohen 1,900 sh (-98.03%)
» More
Q4 2015

VNDA Guru Trades in Q4 2015

Jim Simons 337,390 sh (New)
Paul Tudor Jones 43,204 sh (+5.95%)
John Paulson 3,946,500 sh (unchged)
Steven Cohen Sold Out
» More
Q1 2016

VNDA Guru Trades in Q1 2016

Jim Simons 416,900 sh (+23.57%)
Paul Tudor Jones Sold Out
John Paulson 3,927,000 sh (-0.49%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, HKSE:06826, SZSE:300049, NAS:RGEN, XKRX:048530, ROCO:4105 » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.

Vanda Pharmaceuticals Inc was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.

Ratios

vs
industry
vs
history
Forward P/E 12.02
VNDA's Forward P/E is ranked higher than
74% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. VNDA: 12.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.72
VNDA's P/B is ranked higher than
50% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. VNDA: 3.72 )
Ranked among companies with meaningful P/B only.
VNDA' s P/B Range Over the Past 10 Years
Min: 2.53  Med: 6.02 Max: 623.46
Current: 3.72
2.53
623.46
P/S 3.72
VNDA's P/S is ranked higher than
80% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. VNDA: 3.72 )
Ranked among companies with meaningful P/S only.
VNDA' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 6.35 Max: 69.88
Current: 3.72
2.63
69.88
PFCF 85.55
VNDA's PFCF is ranked lower than
79% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. VNDA: 85.55 )
Ranked among companies with meaningful PFCF only.
VNDA' s PFCF Range Over the Past 10 Years
Min: 33.03  Med: 40.34 Max: 85.55
Current: 85.55
33.03
85.55
POCF 204.13
VNDA's POCF is ranked lower than
95% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. VNDA: 204.13 )
Ranked among companies with meaningful POCF only.
VNDA' s POCF Range Over the Past 10 Years
Min: 0.95  Med: 1.69 Max: 204.13
Current: 204.13
0.95
204.13
Current Ratio 2.95
VNDA's Current Ratio is ranked lower than
65% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. VNDA: 2.95 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.88 Max: 18.62
Current: 2.95
1.67
18.62
Quick Ratio 2.93
VNDA's Quick Ratio is ranked lower than
62% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. VNDA: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.88 Max: 18.62
Current: 2.93
1.64
18.62
Days Inventory 48.48
VNDA's Days Inventory is ranked higher than
80% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. VNDA: 48.48 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 50.28  Med: 151.26 Max: 596.04
Current: 48.48
50.28
596.04
Days Sales Outstanding 50.30
VNDA's Days Sales Outstanding is ranked higher than
61% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. VNDA: 50.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 21.88 Max: 253.93
Current: 50.3
5.22
253.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.35
VNDA's Price/Net Cash is ranked lower than
63% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. VNDA: 8.35 )
Ranked among companies with meaningful Price/Net Cash only.
VNDA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.31  Med: 7.38 Max: 1625
Current: 8.35
0.31
1625
Price/Net Current Asset Value 5.80
VNDA's Price/Net Current Asset Value is ranked lower than
53% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. VNDA: 5.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VNDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.3  Med: 7.37 Max: 185
Current: 5.8
0.3
185
Price/Tangible Book 5.25
VNDA's Price/Tangible Book is ranked lower than
58% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. VNDA: 5.25 )
Ranked among companies with meaningful Price/Tangible Book only.
VNDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 5.51 Max: 356.36
Current: 5.25
0.29
356.36
Price/Median PS Value 0.59
VNDA's Price/Median PS Value is ranked higher than
77% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. VNDA: 0.59 )
Ranked among companies with meaningful Price/Median PS Value only.
VNDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.46  Med: 1.02 Max: 10.51
Current: 0.59
0.46
10.51
Earnings Yield (Greenblatt) (%) -12.31
VNDA's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. VNDA: -12.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VNDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.32  Med: 34.40 Max: 3521.3
Current: -12.31
-14.32
3521.3

More Statistics

Revenue (TTM) (Mil) $121.0
EPS (TTM) $ -0.99
Beta1.74
Short Percentage of Float12.21%
52-Week Range $6.91 - 14.50
Shares Outstanding (Mil)43.15

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 151 201 276
EPS ($) -0.43 0.79 2.29
EPS without NRI ($) -0.43 0.79 2.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:VNDA

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
Vanda Pharmaceuticals Inc. (VNDA)’s Stock Jumps Following NDA Approval May 27 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 26 2016
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance... May 26 2016
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance... May 26 2016
4:30 pm Vanda Pharma announces FDA approval of Co's sNDA for Fanapt May 26 2016
ETF’s with exposure to Vanda Pharmaceuticals, Inc. : May 16, 2016 May 16 2016
VANDA PHARMACEUTICALS INC. Financials May 13 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May... May 13 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 12 2016
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2016 By the Numbers May 11 2016
VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report May 05 2016
Edited Transcript of VNDA earnings conference call or presentation 4-May-16 8:30pm GMT May 05 2016
Vanda reports 1Q loss May 04 2016
Vanda reports 1Q loss May 04 2016
Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 04 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 04 2016
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results May 04 2016
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results May 04 2016
Q1 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close May 04 2016
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 14 2016
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 14 2016
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies Apr 12 2016
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 4, 2016 Apr 04 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Apr 04 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April... Apr 01 2016
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions Mar 28 2016
Vanda reports 4Q loss Feb 10 2016
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day Feb 01 2016
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February... Jan 22 2016
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016... Jan 11 2016
Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals Dec 18 2015
Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer Dec 17 2015
Vanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences Nov 12 2015
Vanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference Nov 04 2015
Vanda reports 3Q loss Nov 03 2015
Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 03 2015
Vanda Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 3, 2015 Oct 15 2015
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book Oct 14 2015
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book Sep 23 2015
Vanda Announces FDA Has Accepted for Review the Fanapt® Supplemental New Drug Application for... Sep 15 2015
Vanda Pharmaceuticals Announces the Appointment of General Counsel Sep 14 2015
Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation Sep 10 2015
Vanda Pharmaceuticals Announces the Appointment of European General Manager Sep 08 2015
Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference Aug 10 2015
HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet Aug 05 2015
Vanda reports 2Q loss Jul 29 2015
Vanda posts 4Q profit Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)